Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hull
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Hull, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company8 AstraZeneca7 Novo Nordisk A/S5 Hoffmann-La Roche4 Ipsen4
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Hull

68 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Eli Lilly and Company
Phase 3
170
Hull, Liverpool, London
2026-09
Recruiting
AstraZeneca
Phase 3
500
Airdrie, Chippenham, Hull, Llandough, Rotherham
2026-08-24
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Newquay, Yeovil, Rotherham, Bristol, Coventry, Hull, Ipswich, Londonderry
2026-08-24
Recruiting
AstraZeneca
Phase 3
1,500
Chippenham, Corby, Dunfermline, Hull, Northwood
2026-08-20
Recruiting
AstraZeneca
Phase 3
900
Blackpool, Glasgow, Hull, Penzance, Sandbach, Thetford, Whitney
2026-07-06
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Blackpool, Aberdeen, Antrim, Bristol, Dundee, Hounslow, Hull, Nuneaton
2026-03-23
Recruiting
Eli Lilly and Company
Phase 4
150
Hull, Leeds, Newmarket
2026-03-09
Active, closed
Kailera
Phase 3
1,270
Truro, Plymouth, Bournemouth, Hull, Glasgow, London, Stevenage, Leicester
2026-01-12
Active, closed
Kailera
Phase 3
2,530
Soham, Torpoint, Hull, Stevenage, Leicester, Nottingham, Newcastle upon Tyne, Bradford
2025-12-18
Recruiting
TrueLok Elevate PMCF Study
NCT07079774Wound of Skin, Ulcers, Soft Tissue Defect
Orthofix s.r.l.
Observational
153
Hull, Newcastle upon Tyne
2025-11-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Blackpool, Bristol, Canterbury, Cardiff, Hull, London, Maidstone, Oxford
2025-10-24
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
DrugSetmelanotide
Rhythm Pharmaceuticals, Inc.
Phase 3
39
London, Birmingham, Hull
2025-09-23
Recruiting
Takeda
Phase 3
347
London, Birmingham, Canterbury, Hull, Leicester, Nottingham, Preston, Sheffield
2025-07-15
Recruiting
Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study
NCT05881798Deep Vein Thrombosis, Venous Thromboembolism, Pulmonary Embolism
Cook Research Incorporated
Observational
82
Leeds, Hull, Liverpool
2025-06-02
Active, closed
AstraZeneca
Phase 3
3,103
Chesterfield, Chippenham, Corby, Coventry, Harrow, Hull, London, Northwood
2025-05-28
By invitation
Novo Nordisk A/S
Observational
1,250
West Bromwich, Barnsley, Hull, London, Luton, Tooting
2025-05-01
Recruiting
AstraZeneca
Phase 3
830
Blackpool, Glasgow, Guildford, Hull, Northwood, Oxford
2025-04-10
Active, closed
Amgen
Phase 3
1,105
Belfast, Birmingham, Blackpool, Bristol, Ely, Glasgow, Hull, Leicester
2025-03-17
Active, closed
Amgen
Phase 3
3,853
Belfast, Birmingham, Blackpool, Bristol, Cornwall, Ely, Glasgow, Hull
2025-03-12
Recruiting
Pfizer
Phase 3
723
Bristol, Milton Keynes, Hull, London, Fazakerley, York, Glasgow, Sheffield
2025-03-11
Recruiting
Daiichi Sankyo
Phase 3
726
Birmingham, Cardiff, Dundee, Hull, Leeds, London, Londonderry, Manchester
2025-02-27
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Birmingham, Hull, Leeds, London, Northwood
2024-12-12
Active, closed
AbbVie
Observational
1,314
Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester
2024-11-26
Recruiting
Eli Lilly and Company
Phase 3
125
Barnsley, Bristol, Cambridge, Dundee, Harrow, Hull, Liverpool
2024-11-18
Recruiting
Eli Lilly and Company
Phase 3
150
Barnsley, Dundee, Hull
2024-11-18
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Aberdeen, Bristol, Camberley, Derby, Edgbaston, Birmingham, Exeter, Glasgow, Hull
2024-11-12
Recruiting
Janssen Research & Development, LLC
Phase 3
1,000
Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton
2024-10-18
Active, closed
Ipsen
Observational
424
Aberdeen, Belfast, Birmingham, Bradford, Hull, London, Newcastle, Nottingham
2024-10-14
Active, closed
Ipsen
Phase 2
670
Exeter, Hull, Liverpool, London
2024-10-10
Active, closed
Heartfelt Technologies
Not applicable
186
Brough, Hull, Croydon, Bury St Edmunds, Horley, Keighley, Cambridge, London
2024-07-11
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
134
Cambridge, Hull, Dundee, Edinburgh
2024-05-28
Active, closed
Eli Lilly and Company
Phase 3
10,000
Aberdeen, Birmingham, Bromborough, Coventry, Glasgow, Hull, Ipswich, Lancashire
2024-04-30
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
High Wycombe, Bristol, Glasgow, Hull, London, Oxford, Portsmouth, Preston
2024-03-13
Active, closed
Eli Lilly and Company
Phase 3
17,300
Blackpool, Bristol, Cheadle, Enfield, Glasgow, Hull, London, Newcastle upon Tyne
2024-03-05
Active, closed
ULTRA LONG: BioFreedom Ultra
NCT05643430Coronary Artery Disease, High Bleeding Risk Patients
Biosensors Europe SA
Not applicable
86
Birmingham, Blackburn, Hull, Lincoln, Newport, Wigan
2024-02-27
Active, closed
Biosensors Europe SA
Not applicable
85
Birmingham, Blackburn, Hull, Lincoln, Newport, Wigan
2024-02-09
Recruiting
OSsIRIS Study - A Post-market Clinical Follow-up Investigation.
NCT06156904Surgically Created Bone Defects or Bone Defects/Voids Resulting From Traumatic Injury
GreenBone Ortho S.p.A.
Observational
135
Hull, Leeds
2024-01-31
Recruiting
Gilead Sciences
Phase 3
402
Hull, Ipswich, Leeds, London, Newcastle upon Tyne, Oxford, Sheffield, Wolverhampton
2023-09-07
Recruiting
GlaxoSmithKline
Phase 3
892
Birmingham, Chelmsford, Cheltenham, Edinburgh, Hull, Leeds West Yorkshire, London, Manchester
2023-08-01
Active, closed
Rhythm Pharmaceuticals, Inc.
Phase 3
143
Birmingham, Hull, London
2023-04-26
Active, closed
Soleno Therapeutics, Inc.
Phase 3
83
Cambridge, Glasgow, Hull, London
2023-01-31
Active, closed
Ipsen
Phase 2
68
Aberdeen, Birmingham, Frimley, Glasgow, Hull, London
2022-12-29
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
885
Woodhurst, Huddersfield, Blackpool, Hull, Liskeard, Manchester, Newquay, Poole
2022-12-13
Active, closed
Bellus Health Inc. - a GSK company
Phase 3
997
Belfast, Bradford, Bristol, Chelmsford, Corby, Coventry, Hayle, Hull
2022-12-05
Active, closed
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Observational
6,000
Bristol, Bedford, Torquay, Hull, Colchester, Gloucester, London, Maidstone
2022-11-21
Active, closed
Eli Lilly and Company
Phase 3
15,374
Blackburn, Bristol, Coventry, Dundee, Ely, Fowey, Hull, Ipswich
2022-10-11
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Hull, London, Newcastle upon Tyne, Salford
2022-09-27
Active, closed
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
NCT05399992Primary Hypercholesterolemia, Mixed Dyslipidemia
Novartis Pharmaceuticals
Observational
847
High Wycombe, Louth, Sunderland, Belfast, Bromwich, Burton-on-Trent, Hull, Lancaster
2022-09-12
Active, closed
AbbVie
Observational
785
Exeter, Hull, Basingstoke, Bury, Kettering, Nottingham, Oxford, Belfast
2022-08-15
Active, closed
Novo Nordisk A/S
Phase 3
412
Cambridge, Hull, Liverpool, London, Manchester, Tooting
2022-08-10
Active, closed
Bausch Health Americas, Inc.
Phase 3
466
Dundee, Hull, Liverpool, Nottingham, Plymouth
2022-08-03
Active, closed
Eli Lilly and Company
Phase 4
780
Aberdeen, Dundee, Ely, Plymouth, Hull, Leicester, Rotherham
2022-08-01
Recruiting
The "Global Paradise System" Registry
NCT05027685Hypertension
ReCor Medical, Inc.
Observational
3,000
Bournemouth, Canterbury, Cardiff, Dudley, Glasgow, Hull, London, Newcastle
2022-01-13
Active, closed
Hoffmann-La Roche
Phase 3
660
Blackpool, GB Manchester, Hull, Leeds, Leicester, London
2021-11-18
Active, closed
Bristol-Myers Squibb
Phase 3
338
Cannock, Hull, London
2021-09-15
Active, closed
Janssen Pharmaceutica N.V., Belgium
Observational
1,314
Aberdeen, Abergavenny, Airdrie, Barnet, Bath, Glasgow, Hull, Leeds
2021-08-25
Active, closed
Bristol-Myers Squibb
Phase 3
729
London, Bradford, Hull, Liverpool, Manchester
2021-07-15
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Belfast, Birmingham, Coventry, Derby, Dundee, Exeter, Hull, Ipswich
2021-04-01
Active, closed
Ipsen
Phase 3
161
Newcastle upon Tyne, Belfast, Camberley, Cambridge, Hull, London, Nottingham, Plymouth
2020-09-24
Active, closed
AstraZeneca
Phase 3
185
Birmingham, Edinburgh, Glasgow, Hull, London, Manchester, Taunton
2020-08-04
Recruiting
Terumo Aortic Global Endovascular Registry
NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Vascutek Ltd.
Observational
1,000
Derby, Hull, Manchester, Oxford
2019-12-17
Active, closed
Novo Nordisk A/S
Phase 2
62
Hull, Liverpool, London, Manchester
2019-07-04
Active, closed
AstraZeneca
Phase 2
401
Dundee, Hull
2018-12-21
Active, closed
AbbVie
Phase 3
1,336
Cambridge, Exeter, Hull, Edinburgh, Glasgow, London, Manchester, Oxford
2018-04-09
Active, closed
Gilead Sciences
Phase 3
340
Birmingham, Hull, London, Newcastle upon Tyne, Nottingham, Plymouth, Portsmouth
2017-12-12
Active, closed
On-X Life Technologies, Inc.
Observational
510
Blackpool, Hull, London, Oxford, Southampton
2015-11-10
Active, closed
Acerta Pharma BV
Phase 3
533
Birmingham, Bournemouth, Cambridge, Cardiff, Greater London, Hull, Leeds, Leicester
2015-07-28
Active, closed
AbbVie
Observational
8,250
Warrington, Darlington, Plymouth, Poole, Hull, London, Basingstoke, Glasgow
2013-04-29
Rows per page Showing 1–68 of 68
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/hull

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 68 of those studies with a site in Hull.

How many clinical trials are recruiting in Hull?

26 of the 68 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 1 have not yet opened recruitment, 40 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hull), 68 studies
PhaseStudiesRecruitingShare
Phase 3452066.2%
Observational14520.6%
Phase 2405.9%
Not applicable304.4%
Phase 4212.9%

Most active sponsors

Lead sponsors with the most studies (Hull)
Lead sponsorStudiesRecruiting
Eli Lilly and Company83
AstraZeneca74
Novo Nordisk A/S51
AbbVie40
Hoffmann-La Roche42
Ipsen40
Amgen20
Biosensors Europe SA20
Bristol-Myers Squibb20
Gilead Sciences21
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.